Navigation Links
In muscular dystrophy, what matters to patients and doctors can differ
Date:7/25/2012

Complex, multi-system diseases like myotonic dystrophy the most common adult form of muscular dystrophy require physicians and patients to identify which symptoms impact quality of life and, consequently, what treatments should take priority. However, a new study out this month in the journal Neurology reveals that there is often a disconnect between the two groups over which symptoms are more important, a phenomenon that not only impacts care but also the direction of research into new therapies.

"In order to design better therapies we must first develop a clear understanding of what patients think are the key mental and physical burdens of this disease," said University of Rochester Medical Center (URMC) neurologist Chad Heatwole, M.D., lead author of the study. "It is clear from this study that, in the case of myotonic dystrophy, researchers have not always been concentrating on the symptoms that are most important to the patient."

Myotonic dystrophy has been characterized as one of the most diverse and complex genetic diseases with a wide range of symptoms ranging from fatigue, muscle weakness, cognitive impairment, depression, difficulty sleeping, impaired vision, pain, difficulty swallowing, gastrointestinal problems, and myotonia, the inability to relax muscles after contraction such as when clenching a fist that is the hallmark of the disease. The severity and onset of these symptoms can vary from patient to patient.

As a result, physicians and patients are often confronted with a bewildering array of treatment options and researchers have previously had no comprehensive method to measure the meaningful impact of experimental therapies. Further impetus for a patient-centered approach has come from a recent push by the federal Food and Drug Administration to require that new drugs take into account what outcomes patients feel are important.

Using a national database of muscular dystrophy patients d
'/>"/>

Contact: Mark Michaud
mark_michaud@urmc.rochester.edu
585-273-4790
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
2. Cedars-Sinai researchers, with stem cells, advance understanding of spinal muscular atrophy
3. University of Nevada School of Medicine researcher reviews muscular dystrophy therapies
4. Clinical trial first to test heart drug regimen for Duchenne muscular dystrophy
5. Jeffrey W. Olin, DO, authors study that describes symptoms and severity of fibromuscular dysplasia
6. Muscular Development Store Releases the Optimum Performance Workout for High Intensity Training
7. New gene transfer strategy shows promise for limb girdle and other muscular dystrophies
8. Mesothelioma Victims Center Now Offers A US Navy Veteran Individual Or Family Dealing With Mesothelioma The Names Of The Best Mesothelioma Attorneys--Quality Matters
9. Mesothelioma Victims Center Urges US Navy Veterans or Anyone with Mesothelioma to Call Them for the Names of the Best Mesothelioma Attorneys in the US-Quality Matters
10. Higher-spending hospitals have fewer deaths for emergency patients
11. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Francisco, September 15, 2014A prospective study that compared ... patients with bone metastases demonstrates that single fraction ... multiple fraction radiation therapy (MFRT) when pain, function ... research presented today at the American Society for ... study indicates that improvements in patients, pain, function ...
(Date:9/16/2014)... Texas (PRWEB) September 16, 2014 Beginning October ... adding a new service offering for its clients who book ... to the volume of business they buy. Most recurring ... during the work week, but others include clients whose ... pet sitter on a daily basis. The ...
(Date:9/16/2014)... Founded by former Miami Beach mayoral candidate Steve ... fighting to legalize medical marijuana in Florida. Advocating for ... recently commissioned a shot-for-shot parody video of the song ... “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called “You’re the Law ... faithfully recreates the carnival scene made famous by John ...
(Date:9/16/2014)... Florida Hospital announced today it is teaming ... partnership and become the Presenting Sponsor of the 2014-15 ... health and wellness partner. As the Presenting Sponsor for ... logo and name inclusion on all Lightning advertising campaigns ... has been a sponsorship partner of the Lightning since ...
(Date:9/16/2014)... reduce the risk of heart disease or stroke, even ... part of the diet. , A study of ... from Monash University,s Department of Epidemiology and Preventive Medicine ... consumption of dairy foods had played in the country,s ... dominantly Chinese food culture, unaccustomed to dairy foods, consuming ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2
... Large study suggests the procedure impairs healthy immune response ... by Caesarean section are at increased risk of asthma, ... the respiratory health of nearly 3,000 infants. , By ... percent) of the children had been diagnosed with asthma ...
... the year. , ... (PRWEB) November 2, 2009 -- For the ... treatment Frontline , to UK mainland addresses, excluding the highlands and islands, ... the Hyperdrug.co.uk web site. , , ,Hyperdrug director Ben Watson says "Hyperdrug ...
... INDIANAPOLIS, Dec. 3 Vertellus Specialties Inc., a leading specialty ... January 1, 2009 for 2-vinylpyridine monomer sales to all non-contract ... investment in production capacity and to provide better supply chain ... About Vertellus Specialties Inc. ...
... positive airway pressure (CPAP) treatment seems to improve cognitive ... from obstructive sleep apnea, according to the results of ... California, San Diego. The study led by Sonia ... Diego School of Medicine and one of the nation,s ...
... the availability of Trade Alerts on stocks making news today. , ... notes for free by visiting: http://www.BeaconEquity.com/m , , ... ), Williams-Sonoma Inc. (NYSE: WSM ), Medicis Pharmaceutical Corp. (NYSE: ... Group Co. (Nasdaq: MHGC ) and DSP Group Inc. (Nasdaq: ...
... the body to selectively suppress the immune response may ... to scientists. , "If you like, what we are ... more like a fetus," said Dr. Andrew L. Mellor, ... and Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics. ...
Cached Medicine News:Health News:C-Section Might Boost Baby's Asthma Risk 2Health News:Beating the Credit Crunch with Hyperdrug.co.uk 2Health News:Treating sleep apnea in Alzheimer's patients helps cognition 2Health News:Treating sleep apnea in Alzheimer's patients helps cognition 3Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: SPC, WSM, MRX, WXS, MHGC, DSPG 2Health News:New approaches to protecting transplanted organs make first steps toward patients 2Health News:New approaches to protecting transplanted organs make first steps toward patients 3
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... DIEGO , Sept. 16, 2014 Imprimis ... pharmaceutical company dedicated to delivering high quality and novel ... announced that Chief Executive Officer Mark Baum ... Annual Craig-Hallum Alpha Select Conference in New York City.  ... its Go Dropless™ campaign in ophthalmology. The presentation ...
(Date:9/16/2014)... -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing ... today that it has entered into an agreement with ... of animal studies for levorphanol, the active ingredient of ... levorphanol.  Gavril Pasternak, MD, PhD, of MSKCC is the ... Pasternak said, "Levorphanol is a unique opioid analgesic that ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... COLLEGEVILLE, Pa., May 30 Wyeth,Pharmaceuticals, a ... today announced the,initiation of the INTORACT (INvestigation ... worldwide randomized, open-label, phase 3b,study comparing TORISEL(R) ... for first-line treatment of patients,with advanced renal ...
... evaluation of safety and tolerability, as ... 2 trials -, ROCKVILLE, Md., May 30 ... that it has initiated dosing in a Phase,1 clinical ... lead IAP,inhibitor, HGS1029, as monotherapy in patients with advanced ...
Cached Medicine Technology:Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 2Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 3Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 4Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 5Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 6Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 2Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 3Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 4
... Rapidlab 800 System is a fully automated, ... care whole blood parameters in addition to ... allows the basic blood gas model to ... electrolytes, metabolites and CO-oximetry in a single ...
Microcomputer controlled, preparative ultracentrifuge, with CFC-free refrigeration system. Available either internally cooled or with external water cooling. Quikset user interface, Softspin automati...
... Sorvall DiscoveryTMM150 SE Micro-ultra centrifuge continues ... volume sample processing, now with 1,048,000 x ... bucket rotor. DiscoveryTMM150SE processes sample sizes ... a small floor footprint, brushless direct drive, ...
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
Medicine Products: